Twenty-nine patients with metastatic breast cancer were treated orally with idarubicin (15 mg/m2 x 3 days every 3-4 weeks). Objective response was seen in 31% of all patients. Toxicity was acceptable. There should be further clinical trials of the new anthracycline antibiotic.
|Number of pages||2|
|Journal||Cancer Treatment Reports|
|Publication status||Published - 1986|
ASJC Scopus subject areas
- Cancer Research